Solubility of sparingly-soluble ionizable drugs

Advanced Drug Delivery Reviews

Volumn 59, Issue 7, 2007, Pages 568-590

  Avdeef, Alex ^a  

^a PION INC   (United States)

Author keywords

Aggregation; Complexation; Dissolution template titration method; Micro dissolution method; Miniaturized shake flask method; pH dependent solubility; Shake flask method; Solubility equations; Sparingly soluble ionizable compounds

Indexed keywords

AGGLOMERATION; COMPLEXATION; COMPUTATIONAL METHODS; DISSOLUTION; IONIZATION; PH EFFECTS; SOLUBILITY; TITRATION;

DISSOLUTION TEMPLATE TITRATION METHODS; MICRO DISSOLUTION METHODS; MINIATURIZED SHAKE FLASK METHODS; SHAKE FLASK METHODS; SOLUBILITY EQUATIONS;

DRUG PRODUCTS;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ASTEMIZOLE; BUTACAINE; CANNABIDIOL; CHLORDIAZEPOXIDE; CINNARIZINE; CLOTRIMAZOLE; DICLOFENAC; DIPYRIDAMOLE; DODECYL SULFATE SODIUM; FLAVOPIRIDOL; FLURBIPROFEN; GEMFIBROZIL; GLIBENCLAMIDE; GRISEOFULVIN; IBUPROFEN; IMATINIB; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MICONAZOLE; NAPROXEN; NATAMYCIN; PAPAVERINE; PHENYTOIN; PROGESTERONE; PROSTAGLANDIN F2 ALPHA; TAUROCHOLIC ACID; TERFENADINE; UNINDEXED DRUG;

ACCURACY; BINDING AFFINITY; CALIBRATION; COMPLEX FORMATION; CRITICAL MICELLE CONCENTRATION; DATA ANALYSIS; DISSOLUTION; DRUG SOLUBILITY; EQUILIBRIUM CONSTANT; GENETIC POLYMORPHISM; LIGAND BINDING; MATHEMATICAL MODEL; MICELLE; MICELLIZATION; MICROTITER PLATE ASSAY; PH; PH MEASUREMENT; PKA; POTENTIOMETRY; PRIORITY JOURNAL; PROTON TRANSPORT; REVIEW; ULTRAVIOLET RADIATION; WETTABILITY;

CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; IONS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POTENTIOMETRY; SOLUBILITY;

EID: 34548039925     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.05.008     Document Type: Review

References (88)

1. Rytting E., Lentz K.A., Chen X.-Q., Qian F., and Venkatesh S. Aqueous and cosolvent solubility data for drug-like organic compounds. The AAPS J. 7 (2005) E78-E105
2. Yalkowsky S.H., and Dannenfelser R.-M. AQUASOL DATAbASE of Aqueous Solubility (1998), College of Pharmacy, Univ. of Arizona 5
3. Abraham M.H., and Le J. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. J. Pharm. Sci. 88 (1999) 868-880
4. Yalkowsky S.H. Solubility and Solubilization in Aqueous Media (1999), Oxford Univ. Press, New York
5. Avdeef A. Absorption and Drug Development (2003), Wiley-Interscience, Hoboken, NJ
6. Grant D.J.W., and Higuchi T. Solutility behavior of organic compounds (1990), John Wiley & Sons, New York
7. Yalkowsky S.H., and Banerjee S. Aqueous Solubility: Methods of Estimation for Organic Compounds (1992), Marcel Dekker, New York
8. Pudipeddi M., Serajuddin A.T.M., Grant D.J.W., and Stahl P.H. Solubility and dissolution of weak acids, bases, and salts. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts: Properties, Selection, and Use (2002), Wiley-VCH, Weinheim 19-39
9. Higuchi T., and Connors A.K. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4 (1965) 117-212
10. Anderson B.D., and Flora K.P. Preparation of water-soluble compounds through salt formation. In: Wermuth C.G. (Ed). The Practice of Medicinal Chemistry (1996), Academic Press, London 739-754
11. Serajuddin A.T.M., and Pudipeddi M. Salt selection strategies. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts: Properties, Selection, and Use (2002), Wiley-VCH, Weinheim 135-160
12. Stahl P.H. Salt selection. In: Hilfiker R. (Ed). Polymorphism in pharmaceutical industry (2006), Wiley-VCH, Weinheim 309-322
13. Brittain H.G. Spectral methods for the characterization of polymorphs and solvates. J. Pharm. Sci. 86 (1997) 405-411
14. Pudipeddi M., and Serajuddin A.T.M. Trends in solubility of polymorphs. J. Pharm. Sci. 94 (2005) 929-939
15. Hancock B.C., and Zografi G. Characterization and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
16. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21 (2004) 201-230
17. Streng W.H. Characterization of Compounds in Solution - Theory and Practice (2001), Kluwer Academic/Plenum Publishers, New York
18. Avdeef A. Physicochemical profiling (solubility, permeability, and charge state). Curr. Top. Med. Chem. 1 (2001) 277-351
19. Avdeef A., Voloboy D., and Foreman A. Dissolution-solubility: pH, buffer, salt, dual-solid, and aggregation effects. In: Testa B., and van de Waterbeemd H. (Eds). Comprehensive medicinal chemistry II Vol. 5 (2007), ADME-TOX Approaches, Elsevier, Oxford, UK 399-423
20. Higuchi T., Shih F.-M., Kimura T., and Rytting J.H. Solubility determination of barely aqueous-soluble organic solids. J. Pharm. Sci. 68 (1979) 1267-1272
21. Venkatesh S., Li J., Xu Y., Vishnuvajjala R., and Anderson B.D. Intrinsic solubility estimation and pH-solubility behavior of cosalane (NSC658586), an extremely hydrphobic diprotic acid. Pharm. Res. 13 (1996) 1453-1459
22. Maurin M.B., Vickery R.D., Gerard C.A., and Hussain M. Solubility of ionization behavior of the antifungal α-(2,4-difluorophenyl)-α -[(1-(2-(2-pyridyl)phenylethenyl)]-1H-1,2,4-triazole-1-ethanol bismesylate (XD405). Int. J. Pharm. 94 (1993) 11-14
23. Attwood D., and Gibson J. Aggregation of antidepressant drugs in aqueous solution. J.Pharm. Pharmacol. 30 (1978) 176-180
24. Bogardus J.B., and Blackwood Jr. R.K. Solubility of doxycycline in aqueous solution. J.Pharm. Sci. 68 (1979) 188-194
25. Streng W.H., Yu D.H.-S., and Zhu C. Determination of solution aggregation using solubility, conductivity, calorimetry, and pH measurement. Int. J. Pharm. 135 (1996) 43-52
26. Zhu C., and Streng W.H. Investigation of drug self-association in aqueous solution using calorimetry, conductivity, and osmometry. Int. J. Pharm. 130 (1996) 159-168
27. Smith S.W., and Anderson B.D. Salt and mesophase formation in aqueous suspensions of lauric acid. Pharm. Res. 10 (1993) 1533-1543
28. Fini A., Fazio G., and Feroci G. Solubility and solubilization properties of non-steroidal antiinflammatory drugs. Int. J. Pharm. 126 (1995) 95-102
29. Avdeef A., Bendels S., Tsinman O., and Kansy M. Solubility-excipient classification gradient maps. Pharm. Res. 24 (2007) 530-545
30. 2∝ (tromethamine salt): solubility behaviour, surface properties, and ionization constants. J. Pharm. Sci. 62 (1973) 1680-1685
31. Jinno J., Oh D.-M., Crison J.R., and Amidon G.L. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J. Pharm. Sci. 89 (2000) 268-274
32. A. Avdeef, High-throughput measurements of solubility profiles, in: B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy (Eds.), Pharmacokinetic Optimization in Drug Research, Verlag Helvetica Chimica Acta, Zürich and Wiley - VCH, Weinheim, 2001, pp. 305-326.
33. Avdeef A., and Testa B. Physicochemical profiling in drug research: a brief state-of-the-art of experimental techniques. Cell. Mol. Life Sci. 59 (2003) 1681-1689
34. Bouligand Y., Boury F., Devoisselle J.-M., Fortune R., Gautier J.-C., Girard D., Maillol H., and Proust J.-E. Ligand crystals and colloids in water-amiodarone systems. Langmuir 14 (1998) 542-546
35. Ravin L.J., Shami E.G., and Rattie E.S. Micelle formation and its relationship to solubility behavior of 2-butyl-3-benzofuranyl-4-(2-(diethylamino) ethoxy)-3,5-diiodophenylketone hydrochloride. J. Pharm. Sci. 64 (1975) 1830-1833
36. a in the solid state. Pharm. Pharmacol. Commun. 4 (1998) 165-178
37. Tinwalla A.Y., Hoesterey B.L., Xiang T.-X., Lim K., and Anderson B.D. Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxy-β-cyclodextrin. Pharm. Res. 10 (1993) 1136-1143
38. Johnson M.D., Hoesterey B.L., and Anderson B.D. Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. J. Pharm. Sci. 83 (1994) 1142-1146
39. Okimoto K., Rajewski R.A., Uekama K., Jona J.A., and Stella V.J. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins. Pharm. Res. 13 (1996) 256-264
40. 7m-β-CD. J. Pharm. Sci. 87 (1998) 926-930
41. Sheng J.J., Kasim N.A., Chandrasekharan R., and Amidon G.L. Solubilization and dissolution of insoluble weak acid, ketoprofen: effect of pH combined with surfactant. Eur. J. Pharm. Sci. 29 (2006) 306-314
42. Miyazaki S., Inouie H., Yamahira T., and Nadai T. Interaction of drugs with bile components. I. Effects of bile salts on the dissolution of indomethacin and phenylbutazone. Chem. Pharm. Bull. 27 (1979) 2468-2472
43. Bakatselou V., Oppenheim R.C., and Dressman J.B. Solubilization and wetting effects of bile salts in the dissolution of steroids. Pharm. Res. 8 (1991) 1461-1469
44. Mithani S.D., Bakatselou V., TenHoor C.N., and Dressman J.B. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 13 (1996) 163-167
45. Luner P.E., Babu S.R., and Radebaugh G.W. The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil. Pharm. Res. 11 (1994) 1755-1760
46. Wei H., and Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29 (2006) 45-52
47. Avdeef A., Berger C.M., and Brownell C. pH-metric solubility. 2. Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharm. Res. 17 (2000) 85-89
48. Avdeef A., and Berger C.M. pH-metric solubility. 3. Dissolution titration template method for solubility determination. Eur. J. Pharm. Sci. 14 (2001) 281-291
49. Glomme A., März J., and Dressman J.B. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J. Pharm. Sci. 94 (2005) 1-16
50. Glomme A., März J., and Dressman J.B. Predicting the intestinal solubility of poorly soluble molecules. In: Testa B., Krämer S.D., Wunderli-Allenspach H., and Folkers G. (Eds). Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies (2006), Wiley-VCH, Weinheim 259-280
51. Bergström C.A.S., Luthman K., and Artursson P. Accuracy of calculated pH-dependent aqueous drug solubility. Eur. J. Pharm. Sci. 22 (2004) 387-398
52. Alsenz J., Meister E., and Haenel E. Development of a partially automated solubility screening (PASS) assay for early drug development. J. Pharm. Sci. 96 (2007) 1748-1762
53. Sugano K., Kato T., Suzuki K., Keiko K., Sujaku T., and Mano T. High throughput solubility measurement with automated polarized light microscopy analysis. J. Pharm. Sci. 95 (2006) 2115-2122
54. Chen T.-M., Shen H., and Zhu C. Evaluation of a method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb. Chem. High Throughput Screen. 5 (2002) 575-581
55. Chen H., Zhang Z., McNulty C., Cameron O., Yoon H.J., Lee J.W., Kim S.C., Seo M.H., Oh H.S., Lemmo A.V., Ellis S.J., and Heimlich K. A high-throughput combinatorial approach for the discovery of a Cremophor EL-free paclitaxel formulation. Pharm. Res. 20 (2003) 1302-1308
56. Pan L., Ho Q., Tsutsui K., and Takahashi L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J. Pharm. Sci. 90 (2001) 521-529
57. Hayward M.J., Hargiss L.O., Munson J.L., Mandiyan S.P., and Wennogle L.P. Validation of Solubility Measurements Using Ultra-Filtration Liquid Chromatography Mass Spectrometry (UF-LC/MS), Amer. Soc. Mass Spec. 48th Annual Conference (2000)
58. Kerns E.H. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90 (2001) 1838-1858
59. Streng W.H., His S.K., Helms P.E., and Tan H.G.H. General treatment of pH-solubility profiles of weak acids and bases and the effect of different acids on the solubility of a weak base. J. Pharm. Sci. 73 (1984) 1679-1684
60. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system (August 2000), FDA, Washington, D.C., USA
61. Wang Z., Burrell L.S., and Lambert W.J. Solubility of E2050 at various pH: a case in which the apparent solubility is affected by the amount of excess solid. J. Pharm. Sci. 91 (2002) 1445-1455
62. Kawakami K., Miyoshi K., and Ida Y. Impact of the amount of excess solids on apparent solubility. Pharm. Res. 22 (2005) 1537-1543
63. Albert A., and Serjeant E.P. The Determination of Ionization Constants. 3rd ed. (1984), Chapman and Hall, London
64. Avdeef A., and Bucher J.J. Accurate measurements of the concentration of hydrogen ions with a glass electrode: calibrations using the prideaux and other universal buffer solutions and a computer-controlled automatic titrator. Anal. Chem. 50 (1978) 2137-2142
65. Avdeef A. pH-metric logP. 2. Refinement of partition coefficients and ionization constants of multiprotic substances. J. Pharm. Sci. 82 (1993) 183-190
66. Bendels S., Tsinman O., Wagner B., Lipp D., Parrilla I., Kansy M., and Avdeef A. PAMPA-excipient classification gradient maps. Pharm. Res. 23 (2006) 2525-2535
67. Herzfeldt C.D., and Kummel R. Dissociation constants, solubilities and dissociation rates of some selected nonsteroidal antiinflammatories. Drug Dev. Ind. Pharm. 9 (1983) 767-793
68. Chiarini A., Tartarini A., and Fini A. pH-solubility relationship and partition coefficients for some anti-inflammatory arylaliphatic acids. Arch. Pharm. 317 (1984) 268-273
69. Chowhan Z.T. pH-solubility profiles of organic carboxylic acids and their salts. J. Pharm. Sci. 67 (1978) 1257-1260
70. Ledwidge M.T., and Corrigan O.I. Effects of surface active characteristics and solid state forms on the pH solubility profiles of drug-salt systems. Int. J. Pharm. 174 (1998) 187-200
71. Schwartz P.A., Rhodes C.T., and Cooper Jr. J.W. Solubility and ionization characteristics of phenytoin. J. Pharm. Sci. 66 (1977) 994-997
72. Bundgaard H., and Johansen M. Pro-drugs as drug delivery systems, VIII Bioreversible derivatization of hydantoin by N-hydroxymethylation. Int. J. Pharm. 5 (1980) 67-77
73. Serajuddin A.T.M., and Rosoff M. pH-solubility profile of papaverine hydrochloride and its relationship to the dissolution rate of sustained-release pellets. J. Pharm. Sci. 73 (1984) 1203-1208
74. Miyazaki S., Inouie H., Nadai T., Arita T., and Nakano M. Solubility characteristics of weak bases and their hydrochloride salts in hydrochloric acid solutions. Chem. Pharm. Bull. 27 (1979) 1441-1447
75. Savolainen J., Järvinen K., Taipale H., Jarho P., Loftsson T., and Järvinen T. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm. Res. 15 (1998) 1696-1701
76. Li P., Esmail S., and Yalkowsky S.H. Combined effect of complexation and pH on solubilization. J. Pharm. Sci. 87 (1998) 1535-1537
77. Koontz J.L., and Marcy J.E. Formation of natamycin-cyclodextrin inclusion complexes and their characterization. J. Agric. Food Chem. 51 (2003) 7106-7110
78. Zingone G., and Rubessa F. Preformulation study of the inclusion complex warfarin-β-cyclodextrin. Int. J. Pharm. 291 (2005) 3-10
79. Wen X., Liu Z., Zhu T., Zhu M., Jiang K., and Huang Q. Evidence for the 2:1 molecular recognition and inclusion behavior between β- and γ-cyclodextrins and cinchonine. Bioorg. Chem. 32 (2004) 223-233
80. 9-tetrahydrocannabinol in rabbits. Eur. J. Pharm. Sci. 26 (2005) 71-77
81. Figueiras A., Sarraguaça J.M.G., Carhalho R.A., Pais A.A.C.C., and Veiga F.J.B. Interaction of omeprazole with a methylated derivative of β-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulation. Pharm. Sci. 24 (2006) 377-389
82. Béni S., Szakács Z., Csernák O., Barcza L., and Noszál B. Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. Eur. J. Pharm. Sci. 30 (2007) 167-174
83. Miyazaki S., Oshiba M., and Nadai T. Precaution on use of hydrochloride salts in pharmaceutical formulation. J. Pharm. Sci. 70 (1981) 594-596
84. Anderson B.D., and Conradi R.A. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci. 74 (1985) 815-820
85. Garren K.W., and Pyter R.A. Aqueous solubility properties of a dibasic peptide-like compound. Int. J. Pharm. 63 (1990) 167-172
86. Engel G.L., Farid N.A., Faul M.M., Richardson L.A., and Winneroski L.L. Salt selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 198 (2000) 239-247
87. Badwan A.A., Alkaysi H.N., Owais L.B., Salem M.S., and Arafat T.A. Terfenadine. Anal. Profiles Drug Subst. 19 (1990) 627-662
88. Wells J.I. Pharmaceutical preformulation: the physicochemical properties of drug substances (1988), Ellis Horwood Ltd., Chichester 32